Some of the tools used to create Covid vaccines and, more recently, lifesaving treatments for that disease were developed by Avantor. On Thursday, the highly ranked medical tools maker's stock Relative Strength (RS) Rating climbed to 74, up from 62 the day before. The rising RS Rating bolsters its other ratings, including a powerful 95 EPS Rating, of a perfect 99. Avantor stock was down fractionally Thursday.
The new 74 Relative Strength Rating shows that watchlist candidate Avantor stock has outperformed 74% of all stocks over the past year. It's a good but not-yet-great number. Research shows that the best-performing stocks often have an RS Rating of above 80 in the early stages of their moves. See if Philadelphia, Pa.-based Avantor can continue to rebound and hit that benchmark.
Avantor Stock Among Top 25% Overall
Avantor makes and sells tools, equipment and chemicals to medical research companies that use them to perform clinical studies. Its customers include the top 10 pharma companies.
Among its other key ratings, Avantor stock has a B SMR Rating (sales+profit margins+return on equity) and a 76 Composite Rating.
Regarding fundamentals, Avantor posted 24% earnings growth last quarter, to 36 cents per share. The prior three periods its EPS grew 106%, 84% and 46%. Sales grew just 7% last quarter amid the market correction, to $1.91 billion. However, the prior three quarters its revenue grew 18%, 26% and 14%.
See How IBD Helps You Make More Money In Stocks
Avantor stock is not currently near a potential buying area. See if the stock goes on to form a sound pattern that could kick off a new price move.
Avantor stock earns the No. 2 rank among its peers in the Medical-Research Equipment/Services industry group. Bio-Techne and Iqvia are also among the top five ranked in the group.
When you're researching the best stocks to buy and watch, be sure to pay attention to relative price strength.
This proprietary Relative Strength Rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of the other stocks in our database.
Please follow James DeTar on Twitter @JimDeTar
